Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study
- 1 August 2016
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 142 (2) , 231-236
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).Journal of Clinical Oncology, 2015
- Positron Emission Tomography–Laparoscopy Based Method in the Prediction of Complete Cytoreduction in Platinum-Sensitive Recurrent Ovarian CancerAnnals of Surgical Oncology, 2014
- A multicentric trial (Olympia–MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2013
- Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experienceGynecologic Oncology, 2013
- Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factorsGynecologic Oncology, 2013
- Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging LaparoscopyOncology, 2008
- Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial DesignJournal of Clinical Oncology, 2004